There are currently 437 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University of Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
NCT06287463
Recruiting
This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Register for Updates
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786
Recruiting
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT05539430
Recruiting
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
Register for Updates
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05231122
Recruiting
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Register for Updates
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
NCT04643002
Recruiting
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York
Conditions: Plasma Cell Myeloma Refractory
Register for Updates
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Research Site, Buffalo, New York
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
NCT05874414
Recruiting
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cholangiocarcinoma
Register for Updates
The Impact of Innovative Tax Proposals on Purchase Patterns
NCT05370313
Recruiting
This study will investigate the effect of four tax proposals (i.e. Tobacco Parity, Nicotine-Content, Harm-Reduction, and Modified Risk Tobacco Product-related taxes) on tobacco product purchasing patterns.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/19/2025
Locations: Roswell Cancer Research Institute, Buffalo, New York
Conditions: Cigarette Smoking
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: State University of New York at Buffalo, Buffalo, New York
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
NCT03865472
Recruiting
This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS) works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a form of brain stimulation therapy that controls nerve cell activity, increases blood flow in the brain, and improves cognitive function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cigarette Smoker, Current Every Day Smoker, Current Smoker
Register for Updates